Experience in setegis (terasosine) administration in early postoperative period after TUR of the prostate


Cite item

Full Text

Abstract

TUR of the prostatic gland for prostatic adenoma was made in 93 patients aged 54-81 years (mean age 64.4 ± 7.5 years). The patients were divided into two groups. Patients of group 1 (n = 31) received no alpha-adrenoblockers, those of group 2 (n = 62) received terasosine in pre- and postoperative period. Group 2 patients demonstrated significant improvement in clinical parameters, postoperative hospital stay for them decreased by 11.3%, side effects were insignificant, their residual urine early after operation was 26.3 ± 8.6 cm3 while 4 weeks after TUR it was 16.3 ± 6.9 cm3. Thus, terasosine (setegis) can be recommended for use in early postoperative period after TUR of the prostate for prostatic adenoma as an effective and safe drug improving postoperative outcome.

References

  1. Isaacs J. T., Coffey D. S. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989; 2 (suppl.): 33-50.
  2. Isaacs J. T. Etiology of benign prostatic hyperplasia. Eur. Urol. 1994; 25 (suppl. 1): 6-9.
  3. Ситдыков Э. Н., Басиашвили Т. Г. Профилактика и лечение обструктивных осложнений после аденомэктомии предстательной железы. Казан. мед. журн. 1989; 70 (2).
  4. Birkhoff J. D. Natural history of benign prostatic hypertrophy. In: Hinman F., ed. Benign prostatic hypertrophy. New York: Springer-Verlag; 1983. 5-9.
  5. Glynn R. J., Campion E. W., Buchard G. R., Silbert J. E. The development of benign prostatic hyperplasia among volunteers in the normative aging study. Am. J. Epidemiol. 1985; 121: 78-90.
  6. Holtgrewe H. L., Mebust W. K., Dowd J. B. et al. Transuretral prostatectomy: practice aspects of the dominant operation in American urology. J. Urol. (Baltimore) 1989; 141: 248-253.
  7. Janknegt R. A. Surgical management for benign prostatic hyperplasia. Prostate 1989; 2 (suppl. 2): 79-93.
  8. Donovan J. L., Peters T. J., Neal D. E. et al. J. Urol. (Baltimore) 2000; 164 (1): 65-70.
  9. Gallucci M., Puppo P., Perachino M. et al. Eur. Urol. 1998; 33: 359-364.
  10. Lepor H. for the Tamsulosin Investigator Group. Urology 1998; 51: 892-900.
  11. Michel M. C. Drugs Today 2001; 37 (suppl. D): 7-11.
  12. Лопаткин И. А. (ред.). Доброкачественная гиперплазия предстательной железы. М.; 1999. 193-209.
  13. Мартов А. Г., Лопаткин Н. А. Руководство по трансуретральной эндоскопической хирургии доброкачественной гиперплазии предстательной железы. М.; 1997.
  14. Sciarra A. Prostate 1998; 34: 121-128.
  15. Bruskewitz R. Eur. Urol. 1999; 36 (suppl. 3): 7-13.
  16. Kirby R., Andersson K. E., Lepor H., Steers W. D. Prostate Cancer Prostat. Dis. 2000; 3: 76-83.
  17. Koshiba K., Egawa S., Ohori M. et al. Does transurethral resection of the prostate pose a risk to life? 22-year outcome. J. Urol. (Baltimore) 1995; 153 (5): 1506-1509.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies